BR112022019625A2 - Formas polimórficas de metopimazina - Google Patents
Formas polimórficas de metopimazinaInfo
- Publication number
- BR112022019625A2 BR112022019625A2 BR112022019625A BR112022019625A BR112022019625A2 BR 112022019625 A2 BR112022019625 A2 BR 112022019625A2 BR 112022019625 A BR112022019625 A BR 112022019625A BR 112022019625 A BR112022019625 A BR 112022019625A BR 112022019625 A2 BR112022019625 A2 BR 112022019625A2
- Authority
- BR
- Brazil
- Prior art keywords
- polymorphic forms
- metopimazine
- mesylate
- kits
- report
- Prior art date
Links
- BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000767 metopimazine Drugs 0.000 title abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 210000000105 enteric nervous system Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formas polimórficas de mesilato de metopimazina são fornecidas neste relatório. Estas formas polimórficas são úteis em métodos, composições e kits para o tratamento de um distúrbio do sistema nervoso entérico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063003998P | 2020-04-02 | 2020-04-02 | |
US16/838,402 US10836757B1 (en) | 2020-04-02 | 2020-04-02 | Polymorphic forms of metopimazine |
PCT/US2021/025319 WO2021202839A1 (en) | 2020-04-02 | 2021-04-01 | Novel polymorphic forms of metopimazine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022019625A2 true BR112022019625A2 (pt) | 2022-11-29 |
Family
ID=73263975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022019625A BR112022019625A2 (pt) | 2020-04-02 | 2021-04-01 | Formas polimórficas de metopimazina |
Country Status (11)
Country | Link |
---|---|
US (4) | US10836757B1 (pt) |
EP (1) | EP4126831A4 (pt) |
JP (1) | JP2023533890A (pt) |
KR (1) | KR20220163980A (pt) |
CN (2) | CN115667234A (pt) |
AU (1) | AU2021246085A1 (pt) |
BR (1) | BR112022019625A2 (pt) |
CA (1) | CA3177743A1 (pt) |
IL (1) | IL296953A (pt) |
MX (1) | MX2022012302A (pt) |
WO (1) | WO2021202839A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
US20240156832A1 (en) * | 2020-12-29 | 2024-05-16 | Neurogastrx, Inc. | Methods of metabolizing metopimazine and its salts |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1092476B (de) | 1958-04-24 | 1960-11-10 | Rhone Poulenc Sa | Verfahren zur Herstellung von Phenthiazinderivaten |
BE786583A (fr) | 1971-07-21 | 1973-01-22 | Rhone Poulenc Sa | Nouveaux derives de la phenothiazine, leur preparation et les compositions qui les contiennent |
IT1202370B (it) | 1976-07-12 | 1989-02-09 | Hoffmann La Roche | Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti |
DE2914788A1 (de) | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4412999A (en) | 1982-04-14 | 1983-11-01 | Merck & Co., Inc. | Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
GB8424709D0 (en) | 1984-10-01 | 1984-11-07 | Minnesota Mining & Mfg | Azine redox dyes and leuco azine dyes |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5244925A (en) | 1987-12-18 | 1993-09-14 | Kabi Pharmacia Aktiebolag | Emulsion for parenteral administration |
CA2011063C (en) | 1989-02-28 | 1999-07-06 | Calum B. Macfarlane | Nicardipine pharmaceutical composition for parenteral administration |
IT1230881B (it) | 1989-06-20 | 1991-11-08 | Angeli Inst Spa | Derivati del r(-) 3-chinuclidinolo |
US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
DK203990D0 (da) | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
US5434174A (en) | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
DE69630527T2 (de) | 1995-06-30 | 2004-08-05 | Novo Nordisk A/S | Vorbeugung einer krankheit mit diabetes charakter |
GB9606076D0 (en) | 1996-03-22 | 1996-05-22 | Univ Birmingham | Diabetes treatment |
US6756056B2 (en) | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
US7098232B1 (en) | 1999-10-22 | 2006-08-29 | Athpharma Limited | Treatment and prevention of gastrointestinal disease using antagonists of partial agonists of 5HT1a receptors |
AU3221401A (en) | 1999-11-30 | 2001-06-12 | Rajesh Jain | Fast dissolving composition with prolonged sweet taste |
US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
US6239122B1 (en) | 2000-01-05 | 2001-05-29 | Joy Ann Steele | Method of treatment of nausea, vomiting, and other disorders using estrogens |
CA2429047A1 (en) | 2000-11-15 | 2002-05-23 | Tap Pharmaceutical Products, Inc. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
US20020108869A1 (en) | 2001-02-09 | 2002-08-15 | Alex Savtchenko | Device and technique for multiple channel patch clamp recordings |
US20070129307A1 (en) | 2001-06-22 | 2007-06-07 | The University Of British Columbia | Insulin epitopes for the treatment of type 1 diabetes |
FR2845914B1 (fr) | 2002-10-18 | 2005-11-04 | Schwarz Pharma Lab | Compose antiemetique a desagregation rapide |
CN100353946C (zh) | 2003-01-13 | 2007-12-12 | 戴诺吉药品有限公司 | 治疗功能性肠病的方法 |
US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
MXPA05009242A (es) | 2003-03-17 | 2006-04-18 | Pfizer Prod Inc | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. |
US20050004155A1 (en) | 2003-04-08 | 2005-01-06 | Boyd Thomas A. | Use of methylnaltrexone to treat irritable bowel syndrome |
US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
US7358271B2 (en) | 2003-09-05 | 2008-04-15 | Williamsburg Holdings Llc | Sulpiride pharmaceutical compositions |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
AU2005272598B2 (en) | 2004-08-12 | 2011-11-17 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
WO2006052626A2 (en) | 2004-11-03 | 2006-05-18 | The Board Of Regents Of The University Of Texas System | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders |
DE602005014671D1 (de) | 2004-12-22 | 2009-07-09 | Janssen Pharmaceutica Nv | Tricyclische delta-opioid-modulatoren |
US20090054319A1 (en) | 2005-03-17 | 2009-02-26 | Microbia, Inc. | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders |
US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
CA2619650A1 (en) | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2008002971A2 (en) | 2006-06-29 | 2008-01-03 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
AU2008232954A1 (en) | 2007-03-30 | 2008-10-09 | Tioga Pharmaceuticals Inc. | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome |
AU2008245580A1 (en) | 2007-04-26 | 2008-11-06 | Craig A. Aronchick | Compositions and methods for transmucosal delivery of domperidone |
US7930033B2 (en) | 2007-08-17 | 2011-04-19 | Jianfeng Chen | Appendicular and rectal stimulator device for digestive and eating disorders |
US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
EP2459194A4 (en) | 2009-07-31 | 2012-12-19 | Clera Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PARKINSON |
AU2010310654B2 (en) | 2009-10-21 | 2015-05-14 | Wisconsin Alumni Research Foundation | Method of preventing Type 1 diabetes |
KR101868326B1 (ko) | 2010-03-04 | 2018-06-19 | 오리온 코포레이션 | 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 |
US8329009B2 (en) | 2010-04-09 | 2012-12-11 | Molecular Devices, Llc | High throughput screening of ion channels |
RS55645B1 (sr) | 2010-06-18 | 2017-06-30 | Altos Therapeutics Llc | Antagonisti d2, postupci za sintezu i postupci upotrebe |
US20120053121A1 (en) | 2010-08-31 | 2012-03-01 | Nationwide Children's Hospital, Inc. | Administration of HB-EGF for the Protection of Enteric Neurons |
US20120101089A1 (en) | 2010-10-26 | 2012-04-26 | Ashwani Agarwal | Anti-Emetic Substance |
WO2013028909A1 (en) | 2011-08-25 | 2013-02-28 | Sova Pharmaceuticals, Inc. | Combination therapy for the treatment of sleep-related breathing disorders |
FR2980976B1 (fr) | 2011-10-10 | 2015-10-16 | Mohamed Skiba | Composition pharmaceutique pour l'administration par voie nasale de la metopimazine |
CA3178035A1 (en) | 2012-12-24 | 2014-07-03 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
US20140183933A1 (en) | 2012-12-27 | 2014-07-03 | Robert Bosch Gmbh | Method of decelerating a vehicle with regenerative and friction braking |
IN2013MU02528A (pt) | 2013-07-31 | 2015-06-26 | Centaur Pharmaceuticals Private Ltd | |
WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
-
2020
- 2020-04-02 US US16/838,402 patent/US10836757B1/en active Active
- 2020-09-29 US US17/036,969 patent/US11390620B2/en active Active
-
2021
- 2021-04-01 CA CA3177743A patent/CA3177743A1/en active Pending
- 2021-04-01 EP EP21780629.8A patent/EP4126831A4/en active Pending
- 2021-04-01 IL IL296953A patent/IL296953A/en unknown
- 2021-04-01 MX MX2022012302A patent/MX2022012302A/es unknown
- 2021-04-01 AU AU2021246085A patent/AU2021246085A1/en active Pending
- 2021-04-01 WO PCT/US2021/025319 patent/WO2021202839A1/en unknown
- 2021-04-01 JP JP2022560244A patent/JP2023533890A/ja active Pending
- 2021-04-01 BR BR112022019625A patent/BR112022019625A2/pt unknown
- 2021-04-01 KR KR1020227037099A patent/KR20220163980A/ko unknown
- 2021-04-01 CN CN202180037189.XA patent/CN115667234A/zh active Pending
- 2021-04-01 US US17/915,256 patent/US20230142366A1/en active Pending
- 2021-04-01 CN CN202310349033.6A patent/CN116514797A/zh active Pending
-
2022
- 2022-06-09 US US17/836,060 patent/US11834445B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP4126831A4 (en) | 2024-04-17 |
US20230142366A1 (en) | 2023-05-11 |
CN116514797A (zh) | 2023-08-01 |
CN115667234A (zh) | 2023-01-31 |
JP2023533890A (ja) | 2023-08-07 |
CA3177743A1 (en) | 2021-10-07 |
US11390620B2 (en) | 2022-07-19 |
US20230086867A1 (en) | 2023-03-23 |
EP4126831A1 (en) | 2023-02-08 |
WO2021202839A1 (en) | 2021-10-07 |
US11834445B2 (en) | 2023-12-05 |
IL296953A (en) | 2022-12-01 |
US20210323954A1 (en) | 2021-10-21 |
KR20220163980A (ko) | 2022-12-12 |
MX2022012302A (es) | 2022-11-08 |
US10836757B1 (en) | 2020-11-17 |
AU2021246085A1 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
BR112022019625A2 (pt) | Formas polimórficas de metopimazina | |
BR112021022504A2 (pt) | Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos | |
CO2019013010A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
EA201891532A1 (ru) | Композиции и способы лечения гемоглобинопатий | |
EA201692370A1 (ru) | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ | |
MX2018003534A (es) | Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural. | |
EA201792443A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
CO2020005116A2 (es) | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr | |
ECSP19029758A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
EA201000219A1 (ru) | Способ и композиция для лечения в-клеточных пролиферативных нарушений | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
CY1123396T1 (el) | Αγωγες συνδυασμου περιλαμβανοντας ιμιδαζοπυραζινονες για την αγωγη ψυχιατρικων και/ή γνωσιακων διαταραχων | |
CL2022001769A1 (es) | Anticuerpos anti-cd73 y usos de estos. | |
CO2021005146A2 (es) | Inhibidores selectivos de rgmc y el uso de los mismos | |
CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
BR112018071592A8 (pt) | inibidores de erbb e usos dos mesmos | |
MX2020006297A (es) | Variantes de cd19. | |
BR112018005331A2 (pt) | inibidores de pcna | |
BR112021025544A2 (pt) | Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos | |
BR112018003928A2 (pt) | métodos para o tratamento de doenças | |
CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
BR112018009745A8 (pt) | compostos heterocíclicos para o tratamento de doença |